Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review

Jackie Bryant; J Picot; L Baxter; G Levitt; I Sullivan; A Clegg

doi:10.1016/j.ejca.2007.06.012

Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review

Jackie Bryant
, J Picot
, L Baxter
, G Levitt
, I Sullivan
, A Clegg

University of Southampton

Research output: Contribution to journal › Review article › peer-review

Abstract

AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.

METHODS: Systematic review using a priori methods.

RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.

CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.

Original language	English
Pages (from-to)	1959-66
Number of pages	8
Journal	European Journal Of Cancer Care
Volume	43
Issue number	13
DOIs	https://doi.org/10.1016/j.ejca.2007.06.012
Publication status	Published - Sept 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anthracyclines/adverse effects
Antibiotics, Antineoplastic/adverse effects
Biomarkers/metabolism
Child, Preschool
Cohort Studies
Heart/drug effects
Heart Diseases/chemically induced
Humans
Neoplasms/drug therapy
Randomized Controlled Trials as Topic
Survivors

Access to Document

10.1016/j.ejca.2007.06.012

Cite this

@article{f08626b1298b4e4aa302dc9daaa86fe2,

title = "Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review",

abstract = "AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.METHODS: Systematic review using a priori methods.RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.",

keywords = "Anthracyclines/adverse effects, Antibiotics, Antineoplastic/adverse effects, Biomarkers/metabolism, Child, Preschool, Cohort Studies, Heart/drug effects, Heart Diseases/chemically induced, Humans, Neoplasms/drug therapy, Randomized Controlled Trials as Topic, Survivors",

author = "Jackie Bryant and J Picot and L Baxter and G Levitt and I Sullivan and A Clegg",

year = "2007",

month = sep,

doi = "10.1016/j.ejca.2007.06.012",

language = "English",

volume = "43",

pages = "1959--66",

journal = "European Journal Of Cancer Care",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "13",

}

TY - JOUR

T1 - Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer

T2 - a systematic review

AU - Bryant, Jackie

AU - Picot, J

AU - Baxter, L

AU - Levitt, G

AU - Sullivan, I

AU - Clegg, A

PY - 2007/9

Y1 - 2007/9

N2 - AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.METHODS: Systematic review using a priori methods.RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.

AB - AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.METHODS: Systematic review using a priori methods.RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.

KW - Anthracyclines/adverse effects

KW - Antibiotics, Antineoplastic/adverse effects

KW - Biomarkers/metabolism

KW - Child, Preschool

KW - Cohort Studies

KW - Heart/drug effects

KW - Heart Diseases/chemically induced

KW - Humans

KW - Neoplasms/drug therapy

KW - Randomized Controlled Trials as Topic

KW - Survivors

U2 - 10.1016/j.ejca.2007.06.012

DO - 10.1016/j.ejca.2007.06.012

M3 - Review article

C2 - 17689066

SN - 0959-8049

VL - 43

SP - 1959

EP - 1966

JO - European Journal Of Cancer Care

JF - European Journal Of Cancer Care

IS - 13

ER -

Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this